AttendMe Owl Logo
AttendMe
Evidence Evolution
HematologyHematology

How This Evidence Evolved

Sickle Cell Therapeutics

From hydroxyurea to gene therapy

10.2

Timeline

Signal

Early observations and pilot data that first suggested a new direction

MSH (1995) randomized adults with sickle cell anemia and at least three painful crises per year to hydroxyurea or placebo. Over mean follow-up of 21 months, median annual crisis rates were 2.5 versus 4.5 (p<0.001). Hydroxyurea also delayed the first and second crises and reduced chest syndrome and transfusions. The investigators advised careful monitoring and noted uncertainty about long-term safety.
Proof

Landmark RCTs and pivotal trials that established the evidence base

SUSTAIN (2017) tested crizanlizumab, an anti-P-selectin antibody. High-dose treatment reduced median annual pain-crisis rates to 1.63 versus 2.98 with placebo over 52 weeks. HOPE (2019) tested voxelotor, an HbS polymerization inhibitor: a hemoglobin increase >1 g/dL at week 24 occurred in 51% with 1,500 mg daily versus 7% with placebo. The ACMG bulletin also lists L-glutamine among agents approved as adjunctive or second-line treatments; that historical statement does not establish present availability.
Now

Current standard of care and ongoing research directions

MSH, SUSTAIN and HOPE tested hydroxyurea, crizanlizumab and voxelotor using different endpoints; those historical trials do not establish present availability. Open questions include access, delivery, conditioning toxicity and combination approaches.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

Can sickle cell disease be cured?+
Casgevy uses CRISPR/Cas9 editing, whereas Lyfgenia uses a lentiviral vector. Both received FDA approval for sickle cell disease on 8 December 2023. Their treatment involves myeloablative busulfan conditioning. Long-term safety and efficacy need further evaluation.
What did hydroxyurea show about painful crises in the 1995 trial?+
Hydroxyurea. MSH (1995) found median annual painful-crisis rates of 2.5 versus 4.5 with placebo in adults with at least three crises yearly. SUSTAIN and HOPE later tested crizanlizumab and voxelotor using different endpoints.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026